Literature DB >> 22104669

Quality, not volume, determines outcome of coronary artery bypass surgery in a university-based community hospital network.

Paul A Kurlansky1, Michael Argenziano, Robert Dunton, Robert Lancey, Edward Nast, Allan Stewart, Timothy Williams, Alex Zapolanski, Helena Chang, Judy Tingley, Craig R Smith.   

Abstract

OBJECTIVES: The present study examined the relationship between hospital and surgeon coronary artery bypass grafting procedural volume, mortality, morbidity, and National Quality Forum care processes in a university-based community hospital quality improvement program.
METHODS: The study population consisted of 2218 consecutive patients undergoing isolated coronary artery bypass grafting from 2007 to 2009 in a university-based quality improvement program that emphasizes involvement of all surgeons in the academic quality endeavor. The endpoints included operative mortality, major morbidity, and National Quality Forum-endorsed process measures as defined by the Society of Thoracic Surgeons. The procedural volume was analyzed as a categorical and continuous variable using general estimating equations, which accounted for clustering effects and which were adjusted for Society of Thoracic Surgeons risk scores and the propensity for operation in a low- versus high-volume program.
RESULTS: The annual program volume ranged from 67 to 292 (median, 136; interquartile range, 88-224) and surgeon volume from 1 to 124 (median, 58; interquartile range, 30-89). The mortality rate among the hospitals was 0.47% to 2.23% (0.8% overall), and the observed/expected mortality ranged from 0 to 1.20 (0.41 overall). When comparing low-volume (<200 cases/year) and high-volume centers, no difference was found in the mortality (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.46-2.54, P = .85), morbidity (OR, 1.34; 95% CI, 0.73-2.43), or any of the medication process measures. No difference was found in mortality (OR, 1.59; 95% CI, 0.81-3.13; P = .18), morbidity (OR, 1.20; 95% CI, 0.86-1.66; P = .28), or medication failure (OR, 0.57, 95% CI, 0.3-1.10; P = .10) between the high- and low-volume surgeons (<87). After adjustment for both the Society of Thoracic Surgeons risk score and the propensity score, no association was found for either hospital or surgeon volume with mortality or morbidity. However, a lack of compliance with National Quality Forum measures was highly predictive of morbidity (OR, 1.51; 95% CI, 1.18-1.93; P = .001), regardless of volume, even after adjustment for predicted risk.
CONCLUSIONS: In the setting of a university-based community hospital quality improvement program, excellent surgical results can consistently be obtained even in relatively low-volume programs. The surgical outcomes were not associated with program or surgeon volume, but were directly correlated with the focus on quality as manifested by compliance with evidence-based quality standards. Meaningful university affiliation might represent a new quality paradigm for cardiac surgery in the community hospital setting.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22104669     DOI: 10.1016/j.jtcvs.2011.10.043

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  How to educate and evaluate cardiothoracic surgeon.

Authors:  Koichi Tabayashi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-09-07

2.  Systematic review and a meta-analysis of hospital and surgeon volume/outcome relationships in colorectal cancer surgery.

Authors:  Ya Ruth Huo; Kevin Phan; David L Morris; Winston Liauw
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  Hospital volume and outcomes of cardiothoracic surgery in Japan: 2005-2009 national survey.

Authors:  Ryuzo Sakata; Hiroyuki Kuwano; Hiroyasu Yokomise
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-10

4.  Increasing hospital volume is not associated with improved survival in out of hospital cardiac arrest of cardiac etiology.

Authors:  Michael T Cudnik; Comilla Sasson; Thomas D Rea; Michael R Sayre; Jianying Zhang; Bentley J Bobrow; Daniel W Spaite; Bryan McNally; Kurt Denninghoff; Uwe Stolz
Journal:  Resuscitation       Date:  2012-02-19       Impact factor: 5.262

5.  Counterpoint: Access to transcatheter aortic valve replacement should not be limited to high-volume surgical centers.

Authors:  Philip Green; Gregg F Rosner; Martin B Leon; Allan Schwartz
Journal:  J Thorac Cardiovasc Surg       Date:  2013-06       Impact factor: 5.209

6.  Contemporary results for proximal aortic replacement in North America.

Authors:  Judson B Williams; Eric D Peterson; Yue Zhao; Sean M O'Brien; Nicholas D Andersen; D Craig Miller; Edward P Chen; G Chad Hughes
Journal:  J Am Coll Cardiol       Date:  2012-09-05       Impact factor: 24.094

7.  Patient Characteristics and Emergency Department Factors Associated with Survival After Sudden Cardiac Arrest in Children and Young Adults: A Cross-Sectional Analysis of a Nationally Representative Sample, 2006-2013.

Authors:  Rie Sakai-Bizmark; Scott M I Friedlander; Emily H Marr; Laurie A Mena; Ismael Corral; Ruey-Kang R Chang
Journal:  Pediatr Cardiol       Date:  2018-05-10       Impact factor: 1.655

8.  Impact of type of procedure and surgeon on EuroSCORE operative risk validation.

Authors:  Fernando A Atik; Claudio Ribeiro da Cunha
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Apr-Jun

9.  ECMO Used in a Refractory Ventricular Tachycardia and Ventricular Fibrillation Patient: A National Case-Control Study.

Authors:  Chih-Yu Chen; Ju Tsai; Tai-Yi Hsu; Wan-Yu Lai; Wei-Kung Chen; Chih-Hsin Muo; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  Is there a volume-quality relationship within the independent treatment centre sector? A longitudinal analysis.

Authors:  Florien Margareth Kruse; M C van Nieuw Amerongen; I Borghans; A S Groenewoud; E Adang; P P T Jeurissen
Journal:  BMC Health Serv Res       Date:  2019-11-21       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.